OBJECTIVE: The impact of reducing immunoglobulin dosage while switching from intravenous to subcutaneous replacement therapy was evaluated. METHODS: Sixty-five patients with primary hypogammaglobulinemia on stable intravenous replacement therapy were included in a monocentric longitudinal trial. IgG trough levels were measured at baseline and during 1 year following the switch to the subcutaneous route. RESULTS: Mean IgG trough level after 12 months of subcutaneous therapy was increased by 5.4 percent (8.37-8.82 g/l, p=0.3), while immunoglobulin dosage had been reduced by 28.3% (151-108 mg/kg/week, p<0.0001). For the patients with the lowest serum IgG level upon intravenous infusions, serum IgG level rose by 37 percent (5.33-7.33 g/l, p=0.003), while mean immunoglobulin dosage was reduced by 36 percent (170-109 mg/kg/week, p=0.04). CONCLUSION: The present study shows that sustained serum IgG levels can be achieved after switching towards subcutaneous replacement despite using reduced immunoglobulin doses.
OBJECTIVE: The impact of reducing immunoglobulin dosage while switching from intravenous to subcutaneous replacement therapy was evaluated. METHODS: Sixty-five patients with primary hypogammaglobulinemia on stable intravenous replacement therapy were included in a monocentric longitudinal trial. IgG trough levels were measured at baseline and during 1 year following the switch to the subcutaneous route. RESULTS: Mean IgG trough level after 12 months of subcutaneous therapy was increased by 5.4 percent (8.37-8.82 g/l, p=0.3), while immunoglobulin dosage had been reduced by 28.3% (151-108 mg/kg/week, p<0.0001). For the patients with the lowest serum IgG level upon intravenous infusions, serum IgG level rose by 37 percent (5.33-7.33 g/l, p=0.003), while mean immunoglobulin dosage was reduced by 36 percent (170-109 mg/kg/week, p=0.04). CONCLUSION: The present study shows that sustained serum IgG levels can be achieved after switching towards subcutaneous replacement despite using reduced immunoglobulin doses.
Authors: P Wood; S Stanworth; J Burton; A Jones; D G Peckham; T Green; C Hyde; H Chapel Journal: Clin Exp Immunol Date: 2007-06-12 Impact factor: 4.330
Authors: C Cunningham-Rundles; F P Siegal; E M Smithwick; A Lion-Boulé; S Cunningham-Rundles; J O'Malley; S Barandun; R A Good Journal: Ann Intern Med Date: 1984-10 Impact factor: 25.391
Authors: V Gouilleux-Gruart; H Chapel; S Chevret; M Lucas; M Malphettes; C Fieschi; S Patel; D Boutboul; M-N Marson; L Gérard; M Lee; H Watier; E Oksenhendler Journal: Clin Exp Immunol Date: 2013-02 Impact factor: 4.330
Authors: J S Orange; B H Belohradsky; M Berger; M Borte; J Hagan; S Jolles; R L Wasserman; J S Baggish; R Saunders; B Grimbacher Journal: Clin Exp Immunol Date: 2012-08 Impact factor: 4.330